Tranexamic acid is a lysine analogue that acts by blocking the lysine‐dependent production of plasmin and resultant fibrinolysis. Plasmin has direct effects on immune function and inflammation, and we have compelling laboratory and clinical evidence demonstrating tranexamic acid may reduce infection risk in surgery.
This multicentre, pragmatic, double‐blind, randomised clinical trial will compare the incidence of surgical site infection and red cell transfusion requirements after IV tranexamic acid and placebo in patients undergoing gastrointestinal surgery
Trial Length & Recruitment Aims
Five years, aiming to recruit 50 patients.